{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:00:49Z","timestamp":1793764849780,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2023-0151"],"award-info":[{"award-number":["6-2023-0151"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Therapy using anabolic and antiresorptive agents in sequence is reportedly effective for severe osteoporosis management. However, evidence for this approach in osteoporotic hip fracture patients remains limited. This study aimed to evaluate the effectiveness of sequential therapy using short-term anabolic agents followed by antiresorptive treatment on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with osteoporotic hip fractures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively reviewed 330 patients with osteoporotic hip fractures between February 2022 and December 2023 and selected 113 patients. The patients were categorized into a sequential group (<jats:italic>n<\/jats:italic>\u2009=\u200968), who received an anabolic agent (teriparatide or romosozumab) for three to six months, followed by two doses of denosumab administered at six-month intervals, and a non-sequential group (<jats:italic>n<\/jats:italic>\u2009=\u200945), who received anabolic agent monotherapy. The primary outcome was mean change in BMD at the lumbar spine (LS), femoral neck (FN), and total hip (TH) at one-year postoperatively. Secondary outcomes were the osteoporosis medication profile and mean change of 25-hydroxyvitamin D\u2083 (25(OH)D\u2083) and BTMs including C-terminal telopeptide (CTX) and procollagen type 1\u00a0N-terminal propeptide (P1NP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The sequential group showed significant increases in LS-, FN-, and TH-BMD at one-year follow-up (3.6\u2009\u00b1\u20093.7%, 4.4\u2009\u00b1\u20097.9%, and 1.9\u2009\u00b1\u20094.1%, respectively; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 for all). In contrast, the non-sequential group showed non-significant changes in BMD at all sites. In the sequential group, CTX levels decreased significantly (0.57\u2009\u00b1\u20090.39 to 0.32\u2009\u00b1\u20090.30 ng\/ml, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), whereas the non-sequential group showed a non-significant increase in CTX levels (0.73\u2009\u00b1\u20090.47 to 0.90\u2009\u00b1\u20090.56 ng\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.44). P1NP levels decreased significantly in the sequential group (88.2\u2009\u00b1\u200965.7 to 66.2\u2009\u00b1\u200962.8\u00a0\u00b5g\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The 25(OH)D\u2083 levels improved in both groups but were higher in the sequential group (20.7\u2009\u00b1\u200911.1 to 37.2\u2009\u00b1\u200913.6 ng\/mL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Sequential therapy with short-term anabolic agents followed by antiresorptive therapy significantly improved BMD and normalized BTMs in patients with osteoporotic hip fractures. This treatment approach may be an effective strategy to enhance bone health and potentially reduce subsequent fracture risk in this high-risk population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13018-025-06084-5","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:20:09Z","timestamp":1752657609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Short-term anabolic agent and sequential therapy to improve bone mineral density and bone turnover markers in patients with osteoporotic hip fractures"],"prefix":"10.1186","volume":"20","author":[{"given":"Jun Young","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Young","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Kang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Woo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuck Min","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Suk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"6084_CR1","doi-asserted-by":"publisher","unstructured":"Migliorini F, Giorgino R, Hildebrand F, Spiezia F, Peretti GM, Alessandri-Bonetti M, et al. Fragility fractures: risk factors and management in the elderly. Med (Kaunas). 2021;57(10). https:\/\/doi.org\/10.3390\/medicina57101119.","DOI":"10.3390\/medicina57101119"},{"issue":"1","key":"6084_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5371\/hp.2024.36.1.55","volume":"36","author":"EM Pflug","year":"2024","unstructured":"Pflug EM, Lott A, Konda SR, Leucht P, Tejwani N, Egol KA. Bone health evaluations and secondary fragility fractures in hip fracture patients. Hip Pelvis. 2024;36(1):55\u201361. https:\/\/doi.org\/10.5371\/hp.2024.36.1.55.","journal-title":"Hip Pelvis"},{"issue":"1","key":"6084_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/s13018-021-02634-9","volume":"16","author":"G Gargano","year":"2021","unstructured":"Gargano G, Poeta N, Oliva F, Migliorini F, Maffulli N. Zimmer natural nail and ELOS nails in Pertrochanteric fractures. J Orthop Surg Res. 2021;16(1):509. https:\/\/doi.org\/10.1186\/s13018-021-02634-9.","journal-title":"J Orthop Surg Res"},{"key":"6084_CR4","doi-asserted-by":"publisher","unstructured":"Maffulli N, Aicale R. Proximal femoral fractures in the elderly: A few things to know, and some to forget. Med (Kaunas). 2022;58(10). https:\/\/doi.org\/10.3390\/medicina58101314.","DOI":"10.3390\/medicina58101314"},{"issue":"1","key":"6084_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s13018-024-05177-x","volume":"19","author":"M Chen","year":"2024","unstructured":"Chen M, Li Y, Yang Y, Zhuang W. Analysis of the risk factors for contralateral refracture after hip fracture surgery in elderly individuals: a retrospective study. J Orthop Surg Res. 2024;19(1):681. https:\/\/doi.org\/10.1186\/s13018-024-05177-x.","journal-title":"J Orthop Surg Res"},{"issue":"11","key":"6084_CR6","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1016\/j.injury.2021.08.007","volume":"52","author":"YP Chen","year":"2021","unstructured":"Chen YP, Kuo YJ, Hung SW, Wen TW, Chien PC, Chiang MH, et al. Loss of skeletal muscle mass can be predicted by sarcopenia and reflects poor functional recovery at one year after surgery for geriatric hip fractures. Injury. 2021;52(11):3446\u201352. https:\/\/doi.org\/10.1016\/j.injury.2021.08.007.","journal-title":"Injury"},{"issue":"1","key":"6084_CR7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1186\/s13018-024-05079-y","volume":"19","author":"AP Schulz","year":"2024","unstructured":"Schulz AP, M\u00fcnch M, Barth T, Kowald B, Frese J, Behrends L, et al. Initial construct stability of long cephalomedullary nails with superior locking for a complex trochanteric fracture model AO31A2.2- a Biomechanical study. J Orthop Surg Res. 2024;19(1):728. https:\/\/doi.org\/10.1186\/s13018-024-05079-y.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"6084_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/bmb\/ldac017","volume":"143","author":"F Migliorini","year":"2022","unstructured":"Migliorini F, Colarossi G, Eschweiler J, Oliva F, Driessen A, Maffulli N. Antiresorptive treatments for corticosteroid-induced osteoporosis: a bayesian network meta-analysis. Br Med Bull. 2022;143(1):46\u201356. https:\/\/doi.org\/10.1093\/bmb\/ldac017.","journal-title":"Br Med Bull"},{"issue":"3","key":"6084_CR9","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/ijms16035452","volume":"16","author":"V Conti","year":"2015","unstructured":"Conti V, Russomanno G, Corbi G, Toro G, Simeon V, Filippelli W, et al. A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from Southern Italy. Int J Mol Sci. 2015;16(3):5452\u201366. https:\/\/doi.org\/10.3390\/ijms16035452.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6084_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/17512433.2021.1851192","volume":"14","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Colarossi G, Baroncini A, Eschweiler J, Tingart M, Maffulli N. Pharmacological management of postmenopausal osteoporosis: a level I evidence Based - Expert opinion. Expert Rev Clin Pharmacol. 2021;14(1):105\u201319. https:\/\/doi.org\/10.1080\/17512433.2021.1851192.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"6084_CR11","doi-asserted-by":"publisher","first-page":"38560","DOI":"10.52965\/001c.38560","volume":"14","author":"E Marsillo","year":"2022","unstructured":"Marsillo E, Pintore A, Asparago G, Oliva F, Maffulli N. Cephalomedullary nailing for reverse oblique intertrochanteric fractures 31A3 (AO\/OTA). Orthop Rev (Pavia). 2022;14(6):38560. https:\/\/doi.org\/10.52965\/001c.38560.","journal-title":"Orthop Rev (Pavia)"},{"issue":"1","key":"6084_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13018-021-02524-0","volume":"16","author":"M Quaranta","year":"2021","unstructured":"Quaranta M, Miranda L, Oliva F, Migliorini F, Pezzuti G, Maffulli N. Haemoglobin and transfusions in elderly patients with hip fractures: the effect of a dedicated orthogeriatrician. J Orthop Surg Res. 2021;16(1):387. https:\/\/doi.org\/10.1186\/s13018-021-02524-0.","journal-title":"J Orthop Surg Res"},{"issue":"7","key":"6084_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4158\/ep-2019-0596","volume":"26","author":"F Cosman","year":"2020","unstructured":"Cosman F. Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture. Endocr Pract. 2020;26(7):777\u201386. https:\/\/doi.org\/10.4158\/ep-2019-0596.","journal-title":"Endocr Pract"},{"issue":"9","key":"6084_CR14","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","volume":"35","author":"S Kumar","year":"2024","unstructured":"Kumar S, Gild ML, McDonald MM, Kim AS, Clifton-Bligh RJ, Girgis CM. A novel sequential treatment approach between denosumab and Romosozumab in patients with severe osteoporosis. Osteoporos Int. 2024;35(9):1669\u201375. https:\/\/doi.org\/10.1007\/s00198-024-07139-9.","journal-title":"Osteoporos Int"},{"key":"6084_CR15","doi-asserted-by":"publisher","first-page":"1759720x2412345","DOI":"10.1177\/1759720x241234584","volume":"16","author":"A Fassio","year":"2024","unstructured":"Fassio A, Gatti D, Biffi A, Ronco R, Porcu G, Adami G, et al. The sequential antifracturative treatment: a meta-analysis of randomized clinical trials. Ther Adv Musculoskelet Dis. 2024;16:1759720x241234584. https:\/\/doi.org\/10.1177\/1759720x241234584.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"6084_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.11005\/jbm.2023.30.4.289","volume":"30","author":"SY Park","year":"2023","unstructured":"Park SY, Kim SH, Lee YK, Shin JH, Ha YC, Chung HY. Position statement: postmenopausal osteoporosis treatment strategies in Korea. J Bone Metab. 2023;30(4):289\u201395. https:\/\/doi.org\/10.11005\/jbm.2023.30.4.289.","journal-title":"J Bone Metab"},{"issue":"9","key":"6084_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1530\/eor-23-0205","volume":"9","author":"DT Arthur Vithran","year":"2024","unstructured":"Arthur Vithran DT, Essien AE, Rahmati M, Opoku M, Keon Yon D, L\u00f3pez S\u00e1nchez GF, et al. Teriparatide in postmenopausal osteoporosis: Uncovering novel insights into efficacy and safety compared to other treatments - a systematic review and meta-analysis. EFORT Open Rev. 2024;9(9):845\u201361. https:\/\/doi.org\/10.1530\/eor-23-0205.","journal-title":"EFORT Open Rev"},{"issue":"1","key":"6084_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13018-025-05545-1","volume":"20","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu X, Wu Y, Luo T. Efficacy and safety of sequential therapy for primary osteoporosis with bone formation promoters followed by bone resorption inhibitors: a meta-analysis. J Orthop Surg Res. 2025;20(1):147. https:\/\/doi.org\/10.1186\/s13018-025-05545-1.","journal-title":"J Orthop Surg Res"},{"key":"6084_CR19","doi-asserted-by":"publisher","first-page":"117189","DOI":"10.1016\/j.bone.2024.117189","volume":"187","author":"R Takahashi","year":"2024","unstructured":"Takahashi R, Chiba K, Okazaki N, Era M, Yokota K, Yabe Y, et al. Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study. Bone. 2024;187:117189. https:\/\/doi.org\/10.1016\/j.bone.2024.117189.","journal-title":"Bone"},{"issue":"4","key":"6084_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00198-022-06626-1","volume":"34","author":"G Yu","year":"2023","unstructured":"Yu G, Tong S, Liu J, Wan Y, Wan M, Li S, et al. A systematic review of cost\u2013effectiveness analyses of sequential treatment for osteoporosis. Osteoporos Int. 2023;34(4):641\u201358. https:\/\/doi.org\/10.1007\/s00198-022-06626-1.","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"6084_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/gl-2020-0524suppl","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, american association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update, et al. endocr pract. 2020;26(Suppl 1):1\u201346. https:\/\/doi.org\/10.4158\/gl-2020-0524suppl.","journal-title":"Endocr Pract"},{"issue":"9999","key":"6084_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(15)61120-5.","journal-title":"Lancet"},{"issue":"7","key":"6084_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, et al. FRAME study: the foundation effect of Building bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Min Res. 2018;33(7):1219\u201326. https:\/\/doi.org\/10.1002\/jbmr.3427.","journal-title":"J Bone Min Res"},{"issue":"1","key":"6084_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s40520-024-02736-4","volume":"36","author":"C Dorilleau","year":"2024","unstructured":"Dorilleau C, Kanagaratnam L, Charlot I, Hittinger A, Bertin E, Salmon JH, et al. The least significant change on bone mineral density scan increased in patients with higher degrees of obesity. Aging Clin Exp Res. 2024;36(1):98. https:\/\/doi.org\/10.1007\/s40520-024-02736-4.","journal-title":"Aging Clin Exp Res"},{"key":"6084_CR25","doi-asserted-by":"publisher","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","volume":"139","author":"B Langdahl","year":"2020","unstructured":"Langdahl B. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone. 2020;139:115516. https:\/\/doi.org\/10.1016\/j.bone.2020.115516.","journal-title":"Bone"},{"issue":"2","key":"6084_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jbmr\/zjae179","volume":"40","author":"N Hong","year":"2025","unstructured":"Hong N, Shin S, Kim H, Cho SJ, Park JA, Rhee Y. Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women. J Bone Min Res. 2025;40(2):184\u201392. https:\/\/doi.org\/10.1093\/jbmr\/zjae179.","journal-title":"J Bone Min Res"},{"issue":"4","key":"6084_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","volume":"101","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016;101(4):1353\u201363. https:\/\/doi.org\/10.1210\/jc.2015-4181.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6084_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s13018-021-02497-0","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Spiezia F, Peretti GM, Tingart M, Giorgino R. Potential of biomarkers during Pharmacological therapy setting for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res. 2021;16(1):351. https:\/\/doi.org\/10.1186\/s13018-021-02497-0.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"6084_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13018-021-02474-7","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Spiezia F, Tingart M, Maria PG, Riccardo G. Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res. 2021;16(1):318. https:\/\/doi.org\/10.1186\/s13018-021-02474-7.","journal-title":"J Orthop Surg Res"},{"issue":"9886","key":"6084_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/s0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(13)60856-9.","journal-title":"Lancet"},{"issue":"9","key":"6084_CR31","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. Patients between 2002 and 2011. J Bone Min Res. 2014;29(9):1929\u201337. https:\/\/doi.org\/10.1002\/jbmr.2202.","journal-title":"J Bone Min Res"},{"issue":"1","key":"6084_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11657-022-01201-x","volume":"18","author":"H Hagino","year":"2023","unstructured":"Hagino H, Yoshinaga Y, Hamaya E, Lin TC, Ajmera M, Meyers J. A real-world study of treatment patterns among patients with osteoporotic fracture: analysis of a Japanese hospital database. Arch Osteoporos. 2023;18(1):23. https:\/\/doi.org\/10.1007\/s11657-022-01201-x.","journal-title":"Arch Osteoporos"},{"issue":"4","key":"6084_CR33","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00198-016-3886-y","volume":"28","author":"A Modi","year":"2017","unstructured":"Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int. 2017;28(4):1355\u201363. https:\/\/doi.org\/10.1007\/s00198-016-3886-y.","journal-title":"Osteoporos Int"},{"issue":"1","key":"6084_CR34","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1186\/s13018-024-05263-0","volume":"19","author":"T Liu","year":"2024","unstructured":"Liu T, Zhang X, Zhang J, Ye P, Yang M, Tian M. Effect of the orthogeriatric co-management on older hip fracture patients with multimorbidity: a post-hoc exploratory subgroup analysis of a non-randomised controlled trial. J Orthop Surg Res. 2024;19(1):780. https:\/\/doi.org\/10.1186\/s13018-024-05263-0.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"6084_CR35","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1186\/s13018-024-05219-4","volume":"19","author":"X Han","year":"2024","unstructured":"Han X, Han L, Chu F, Liu B, Song F, Jia D, et al. Predictors for 1-year mortality in geriatric patients following fragile intertrochanteric fracture surgery. J Orthop Surg Res. 2024;19(1):701. https:\/\/doi.org\/10.1186\/s13018-024-05219-4.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"6084_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1186\/s13018-024-05136-6","volume":"19","author":"J Huang","year":"2024","unstructured":"Huang J, Lin L, Lyu J, Fang X, Zhang W. Hip arthroplasty following failure of internal fixation in intertrochanteric femoral fractures: classification decision-making for femoral stem selection and clinical validation. J Orthop Surg Res. 2024;19(1):671. https:\/\/doi.org\/10.1186\/s13018-024-05136-6.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"6084_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1186\/s12891-020-03771-8","volume":"21","author":"CH Park","year":"2020","unstructured":"Park CH, Yoo JI, Choi CH, Suh YS. The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study. BMC Musculoskelet Disord. 2020;21(1):751. https:\/\/doi.org\/10.1186\/s12891-020-03771-8.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"6084_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a bayesian network meta-analysis. J Orthop Surg Res. 2021;16(1):533. https:\/\/doi.org\/10.1186\/s13018-021-02678-x.","journal-title":"J Orthop Surg Res"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-06084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-025-06084-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-06084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:20:10Z","timestamp":1752657610000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-025-06084-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6084"],"URL":"https:\/\/doi.org\/10.1186\/s13018-025-06084-5","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Yongin Severance Hospital (9-2025-0038).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Review Committee Statement."}}],"article-number":"662"}}